読み込み中
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
通常取引
$16.4895
−$0.5005 · -2.95%
日中の時刻はETです。市場データは遅延する場合があります。
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
日中レンジ
現在 $16.4895
52週レンジ
現在 $16.4895
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
30
割高
センチメント
60
まちまち
リスク
34
中程度のリスク
モメンタム
70
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
日中レンジ
現在 $16.4895
52週レンジ
現在 $16.4895
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.72億 USD | 2368万 USD | — | — | 1.4億 USD |
| 売上原価 | 697万 USD | 82.6万 USD | — | — | — |
| 粗利益 | 1.65億 USD | 2285.4万 USD | — | — | 1.4億 USD |
| 研究開発 | 2.59億 USD | 2.42億 USD | 1.63億 USD | 1.18億 USD | 8824.8万 USD |
| 販売・一般管理 | 1.8億 USD | 1.21億 USD | 6692.2万 USD | 3325.8万 USD | 2524.1万 USD |
| 営業費用 | 4.38億 USD | 3.63億 USD | 2.3億 USD | 1.52億 USD | 1.13億 USD |
| 受取利息 | 2273万 USD | 2609万 USD | 2116.3万 USD | 587.2万 USD | 40.3万 USD |
| 支払利息 | 3378.5万 USD | 492.9万 USD | 20.8万 USD | 313.7万 USD | 189.9万 USD |
| 減価償却費と償却費 | 6000 USD | 8000 USD | 1.2万 USD | 3.3万 USD | 4.3万 USD |
| 営業利益 | −2.73億 USD | −3.4億 USD | −2.3億 USD | −1.52億 USD | 2622万 USD |
| 純利益 | −2.85億 USD | −3.19億 USD | −2.09億 USD | −1.49億 USD | 2492.6万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$36.67
上昇余地（122.38%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI5468.17万0.00%2.3兆 USD0.03%$381.44-0.13%
State Street SPDR S&P Biotech ETFXBI4260.96万0.43%98.74億 USD0.35%$151.57-1.43%
iShares Russell 2000 ETFIWM3933.94万0.05%787.4億 USD0.19%$278.25-0.25%
Vanguard Extended Market ETFVXF1989.04万0.02%954億 USD0.05%$233.86-0.49%
iShares Russell 2000 Growth ETFIWO1394.85万0.10%139.17億 USD0.24%$354.13-0.74%
iShares Biotechnology ETFIBB1077万0.10%108.2億 USD0.44%$204.37-1.03%
Vanguard Russell 2000 ETFVTWO987.37万0.05%180億 USD0.06%$112.39-0.24%
Schwab U.S. Small-Cap ETFSCHA801.61万0.04%218.24億 USD0.03%$32.715-0.23%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
